Reference is made to the stock exchange announcement by Lifecare ASA (the
"Company") dated 2 June 2025 regarding the commencement of the exercise period
for 4,193,806 warrants (the "Warrants") issued in connection with the
partially underwritten rights issue of new shares in the Company completed in
June 2024 (the "Rights Issue").

Each Warrant gives the holder a right to subscribe for one new share in the
Company at an exercise price per share of NOK 5.31681. The Warrants are listed
and tradable on Euronext Oslo Stock Exchange under the ticker code "LIFES".
Warrants that are not exercised to subscribe for new shares before the end of
the Exercise Period at 16:30 hours (CEST) on 13 June 2025 or sold before 16:30
hours (CEST) on 6 June 2025 will have no value and will lapse without
compensation to the holder. Holders of Warrants who do not exercise their
Warrants within the Exercise Period may experience a dilution of their
shareholding in the Company.

The Company has been informed that Teigland AS, a company closely related to
Trine Teigland, Board member and primary insider of Lifecare ASA, has
exercised 100,922 Warrants, for the allocation of 100,922 New Shares in the
Company at a price per New Share of NOK 5.31681.

Please see details about the transaction in the attached form.

Subject to timely payment of the aggregate exercise amount for the new shares
on 19 June 2025, the Company expects that the share capital increase
pertaining to the issuance of the new shares will be registered with the
Norwegian Register of Business Enterprises on or about 24 June 2025 and that
shares will be delivered to the VPS accounts of the subscribers to whom they
are allocated on or about 25 June 2025.

The shares received upon exercise of Warrants will be listed on Euronext Oslo
Børs under ISIN NO0013355859 and ticker code "LIFE". The shares will be listed
as soon as the new shares are fully paid, the share capital increase
pertaining to the issuance of the new shares has been registered in the
Norwegian Register of Business Enterprises, and the new shares have been
issued in the VPS.

The shares received upon exercise of Warrants may not be transferred or traded
before (i) the new shares have been fully paid, (ii) the share capital
increase pertaining to the issuance of the new shares has been registered with
the Norwegian Register of Business Enterprises, and (iii) the new shares have
been issued in the VPS.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication at
2025-06-05 12:52 CEST.